A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
Public ClinicalTrials.gov record NCT06702449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Seamless Phase 1/2, Observer-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Immunogenicity of a UTI Vaccine When Administered to Adults 18 Through 64 Years of Age and Clinical Efficacy When Administered to Females 18 Through 64 Years of Age
Study identification
- NCT ID
- NCT06702449
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 448 participants
Conditions and interventions
Conditions
Interventions
- Candidate UTI vaccine HTD formulation 2 Combination Product
- Candidate UTI vaccine high dose formulation 1 Combination Product
- Candidate UTI vaccine high dose formulation 2 Combination Product
- Candidate UTI vaccine low dose formulation 1 Combination Product
- Candidate UTI vaccine low dose formulation 2 Combination Product
- Candidate UTI vaccine medium dose formulation 1 Combination Product
- Candidate UTI vaccine medium dose formulation 2 Combination Product
- Placebo Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2024
- Primary completion
- May 30, 2027
- Completion
- May 30, 2027
- Last update posted
- Apr 20, 2026
2024 – 2027
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Lenexa | Kansas | 66219 | Recruiting |
| GSK Investigational Site | Secaucus | New Jersey | 07094 | Recruiting |
| GSK Investigational Site | Rochester | New York | 14609 | Recruiting |
| GSK Investigational Site | Weatherford | Texas | 76086 | Recruiting |
| GSK Investigational Site | Seattle | Washington | 98104 | Recruiting |
| GSK Investigational Site | Wenatchee | Washington | 98801 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06702449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced Apr 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06702449 live on ClinicalTrials.gov.